当前位置：
X-MOL 学术
›
JAMA Neurol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
JAMA Neurology ( IF 29.0 ) Pub Date : 2024-02-12 , DOI: 10.1001/jamaneurol.2023.5566 Nail Benallegue 1, 2 , Fabien Rollot 3, 4, 5, 6 , Sandrine Wiertlewski 2, 7 , Romain Casey 3, 4, 5, 6 , Marc Debouverie 8 , Anne Kerbrat 9 , Jérôme De Seze 10 , Jonathan Ciron 11, 12 , Aurelie Ruet 13, 14 , Pierre Labauge 15 , Elisabeth Maillart 16 , Helene Zephir 17 , Caroline Papeix 18 , Gilles Defer 19 , Christine Lebrun-Frenay 20 , Thibault Moreau 21 , Eric Berger 22 , Bruno Stankoff 23 , Pierre Clavelou 24 , Olivier Heinzlef 25 , Jean Pelletier 26 , Eric Thouvenot 27, 28 , Abdullatif Al Khedr 29 , Bertrand Bourre 30 , Olivier Casez 31 , Philippe Cabre 32 , Abir Wahab 33 , Laurent Magy 34 , Sandra Vukusic 3, 4, 5, 6 , David-Axel Laplaud 2, 7 , Cotton François 35 , Douek Pascal 35 , Pachot Alexandre 35 , Olaiz Javier 35 , Rigaud-Bully Claire 35 , Marignier Romain 35 , Le Page Emmanuelle 35 , Collongues Nicolas 35 , Cohen Mikaël 35 , Fromont Agnès 35 , Audoin Bertrand 35 , Giannesini Claire 35 , Gout Olivier 35 , Camdessanché Jean-Philippe 35 , Moulin Solène 35 , Doghri Ines 35 , Ben Nasr Haifa 35 , Hankiewicz Karolina 35 , Pottier Corinne 35 , Neau Jean-Philippe 35 , Labeyrie Céline 35 , Nifle Chantal 35 ,
JAMA Neurology ( IF 29.0 ) Pub Date : 2024-02-12 , DOI: 10.1001/jamaneurol.2023.5566 Nail Benallegue 1, 2 , Fabien Rollot 3, 4, 5, 6 , Sandrine Wiertlewski 2, 7 , Romain Casey 3, 4, 5, 6 , Marc Debouverie 8 , Anne Kerbrat 9 , Jérôme De Seze 10 , Jonathan Ciron 11, 12 , Aurelie Ruet 13, 14 , Pierre Labauge 15 , Elisabeth Maillart 16 , Helene Zephir 17 , Caroline Papeix 18 , Gilles Defer 19 , Christine Lebrun-Frenay 20 , Thibault Moreau 21 , Eric Berger 22 , Bruno Stankoff 23 , Pierre Clavelou 24 , Olivier Heinzlef 25 , Jean Pelletier 26 , Eric Thouvenot 27, 28 , Abdullatif Al Khedr 29 , Bertrand Bourre 30 , Olivier Casez 31 , Philippe Cabre 32 , Abir Wahab 33 , Laurent Magy 34 , Sandra Vukusic 3, 4, 5, 6 , David-Axel Laplaud 2, 7 , Cotton François 35 , Douek Pascal 35 , Pachot Alexandre 35 , Olaiz Javier 35 , Rigaud-Bully Claire 35 , Marignier Romain 35 , Le Page Emmanuelle 35 , Collongues Nicolas 35 , Cohen Mikaël 35 , Fromont Agnès 35 , Audoin Bertrand 35 , Giannesini Claire 35 , Gout Olivier 35 , Camdessanché Jean-Philippe 35 , Moulin Solène 35 , Doghri Ines 35 , Ben Nasr Haifa 35 , Hankiewicz Karolina 35 , Pottier Corinne 35 , Neau Jean-Philippe 35 , Labeyrie Céline 35 , Nifle Chantal 35 ,
Affiliation
Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus.
更新日期：2024-02-12
京公网安备 11010802027423号